Clinical Trial Update: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing DFV890 and MAS825 for reducing inflammatory markers in adults with coronary heart disease and clonal hematopoiesis of indeterminate po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clonal Hematopoiesis of Indeterminate Potential
• Coronary Heart Disease

Drugs mentioned

• DFV890
• MAS825

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP) | Phase 2 | Status: COMPLETED | Results posted: 2026-03-27